ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

One Year Outcomes of Low-Dose vs Very Low-Dose Extended-Release Tacrolimus/Mycophenolate mofetil in De Novo Kidney Transplantation: A Multi-Center Randomized Controlled Trial.

Y. Hidaka,1 S. Yamanaga,1 M. Toyoda,1 S. Narumi,2 Y. Watarai,2 T. Kobayashi.3

1Kidney Center, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan
2Transplant Surgery, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Aichi, Japan
3Kidney Transplantation, Aichi Medical University, Nagoya, Aichi, Japan

Meeting: 2017 American Transplant Congress

Abstract number: D87

Keywords: FK506, Immunosuppression, Pharmacokinetics

Session Information

Date: Tuesday, May 2, 2017

Session Name: Poster Session D: Kidney Immunosuppression: Novel Regimens and Drug Minimization

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall D1

Related Abstracts
  • Extended-Release Tacrolimus Plus Everolimus vs Extended-Release Tacrolimus Plus Micophenolate Mofetil in Primary Deceased Donor Kidney Transplant Recipients: 1-Year Results of an Open Label, Randomized Phase 2 Clinical Trial
  • De Novo Low-Dose Sirolimus versus Mycophenolate Mofetil in Combination with Extended-Release Tacrolimus in Kidney Transplant Recipients.

Purpose: Once-daily tacrolimus extended-release formulation (TACER) has now been widely accepted in kidney transplant field. However, the optimal dosage for TACER is still not known.

Patients and Methods: In this multi-center, randomized controlled trial, 62 living-donor kidney transplant recipients were assigned to 2 groups; low-dose (LD) group (n=32): target tacrolimus level for estimated area under curve (eAUC) 0-24 was set for 250ng[bull]hr/ml during the first 1 months, then reduced to 200ng[bull]hr/ml 3 months after transplantation, and very low-dose (VLD) group (n=30): initial target eAUC0-24 was 200ng[bull]hr/ml and 150ng[bull]hr/ml thereafter. All patients received basiliximab induction, mycophenolate mofetil (MMF) and corticosteroid. MMF was started with 1250mg BID and reduced to 750mg BID at 2 weeks after transplant, and adjusted to achieve eAUC0-12 at 30-60[mu]g[bull]hr/L. The primary outcomes were acute rejection, graft/patient survivals, and cytomegalovirus (CMV) infection.

Results: One-year graft and patient survival rates were 100% in both groups, and acute rejections were 0% in LD group and 10.0% in VLD group (p=0.11). Mean estimated glomerular filtration rates at 1 year were similar among the two groups (LD: 50.9±13.3ml/min/1.73m2 and VLD: 51.6±12.6ml/min/1.73m2, p=0.81). The incidences of CMV infection were lower in VLD group (LD 12.5% and VLD 6.7%, p=0.37). Calcineurin inhibitor toxicity found on protocol biopsy was observed more in VLD group at 1 month, but similar at 1 year (1 month: LD 6.3% vs VLD 17.2%, p=0.17; 1 year: LD 10.0% vs VLD 11.5%, p=0.59). Actual mean tacrolimus trough and eAUC0-24 levels at 1 month & 1 year were as follows; LD: 5.6±1.7 & 5.0±0.9ng/ml, 240.8±43.1 & 206.5±27.2ng[bull]hr/ml, and VLD: 4.8±1.2 & 3.4±0.9ng/ml, 211.7±37.2 & 149.9±40.8ng[bull]hr/ml. There were significant differences in tacrolimus trough level and eAUC in 1, 3, 6 months and 1 year after transplantation (p<0.05).

Conclusion: The very low-dose TACER regimen under eAUC monitoring showed similar acute rejection and graft / patient survivals to low-dose after kidney transplantation.

CITATION INFORMATION: Hidaka Y, Yamanaga S, Toyoda M, Narumi S, Watarai Y, Kobayashi T. One Year Outcomes of Low-Dose vs Very Low-Dose Extended-Release Tacrolimus/Mycophenolate mofetil in De Novo Kidney Transplantation: A Multi-Center Randomized Controlled Trial. Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Hidaka Y, Yamanaga S, Toyoda M, Narumi S, Watarai Y, Kobayashi T. One Year Outcomes of Low-Dose vs Very Low-Dose Extended-Release Tacrolimus/Mycophenolate mofetil in De Novo Kidney Transplantation: A Multi-Center Randomized Controlled Trial. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/one-year-outcomes-of-low-dose-vs-very-low-dose-extended-release-tacrolimusmycophenolate-mofetil-in-de-novo-kidney-transplantation-a-multi-center-randomized-controlled-trial/. Accessed March 7, 2021.

« Back to 2017 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Home
  • Search
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.